<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03324243</url>
  </required_header>
  <id_info>
    <org_study_id>ARO-014</org_study_id>
    <nct_id>NCT03324243</nct_id>
  </id_info>
  <brief_title>A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase II Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arog Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arog Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, multicenter, single-arm study to assess the safety and feasibility of&#xD;
      combining crenolanib with fludarabine and cytarabine chemotherapy in pediatric patients with&#xD;
      relapsed/refractory FLT3-mutated AML. Patients will receive up to two courses of salvage&#xD;
      chemotherapy with fludarabine, cytarabine, and crenolanib. Response will be assessed between&#xD;
      day 29-43 of each course.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn: Study halted prior to enrollment of first participant&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients experiencing ≥ Grade 3 adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>From study entry to 30 days post-treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients experiencing Grade 4 adverse events related to crenolanib as assessed by CTCAE v4.0</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of early mortality</measure>
    <time_frame>60 days</time_frame>
    <description>Number of patients who died within 60 days of start of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>4 years</time_frame>
    <description>EFS is defined as the time from the date of start of treatment to the date of failure to achieve a remission, relapse, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>4 years</time_frame>
    <description>RFS is defined as the time from the date of remission to date of relapse or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>4 years</time_frame>
    <description>OS is defined as the time from the date of start of treatment until death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Relapsed/Refractory FLT3-mutated AML</condition>
  <arm_group>
    <arm_group_label>Crenolanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crenolanib</intervention_name>
    <description>66.7 mg/m2 three times a day (TID)</description>
    <arm_group_label>Crenolanib</arm_group_label>
    <other_name>Crenolanib besylate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2/day, intravenous infusions over 30 mins.</description>
    <arm_group_label>Crenolanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>2000 mg/m2/day, intravenous infusions over 1-3 hours.</description>
    <arm_group_label>Crenolanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 1 years and ≤ 21 years&#xD;
&#xD;
          2. Confirmed diagnosis of AML according to World Health Organization (WHO) 2016&#xD;
             classification&#xD;
&#xD;
          3. Definitive evidence of a FLT3-ITD and/or FLT3-TKD (D835/I836) mutation at the time of&#xD;
             enrollment&#xD;
&#xD;
          4. Patients must have histologically or molecularly confirmed relapsed or refractory AML&#xD;
&#xD;
          5. Karnofsky or Lansky performance score ≥ 50. Use Karnofsky for patients &gt; 16 years old&#xD;
             and Lansky for patients ≤ 16 years of age.&#xD;
&#xD;
          6. Adequate renal function, defined as:&#xD;
&#xD;
               -  Creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2 or&#xD;
&#xD;
               -  Normal serum creatinine based on age/gender&#xD;
&#xD;
          7. Adequate liver function, defined as:&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5x ULN for age,&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST) ≤ 3.0x ULN for age, and&#xD;
&#xD;
               -  Serum alanine aminotransferase (ALT) ≤ 3.0x ULN for age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any of the following current or previous diagnoses:&#xD;
&#xD;
               -  Acute promyelocytic leukemia (APL)&#xD;
&#xD;
               -  Down syndrome&#xD;
&#xD;
               -  DNA fragility or bone marrow failure syndromes (such as Fanconi anemia, Bloom&#xD;
                  syndrome, Kostmann syndrome, or Shwachman syndrome)&#xD;
&#xD;
               -  AML secondary to prior MDS/MPN, including chronic myelomonocytic leukemia and&#xD;
                  juvenile myelomonocytic leukemia&#xD;
&#xD;
               -  Blastic plasmacytoid dendritic cell neoplasm&#xD;
&#xD;
               -  Acute leukemia of ambiguous lineage&#xD;
&#xD;
               -  B-lymphoblastic leukemia/lymphoma&#xD;
&#xD;
               -  T-lymphoblastic leukemia/lymphoma, including early T-cell precursor lymphoblastic&#xD;
                  leukemia (ETP-ALL)&#xD;
&#xD;
          2. Patients who are refractory to first line (induction and re-induction) and a second&#xD;
             line (1st salvage) treatment for AML.&#xD;
&#xD;
          3. Patients who have received more than 1 prior allogeneic HSCT&#xD;
&#xD;
          4. Patients will be excluded if they have a systemic fungal, bacterial, viral or other&#xD;
             infection of which they exhibit ongoing signs/symptoms related to the infection&#xD;
             without improvement despite appropriate antibiotics or other treatment.&#xD;
&#xD;
          5. Patients will be excluded if there is a plan to administer non-protocol chemotherapy,&#xD;
             radiation therapy, or immunotherapy during the study period.&#xD;
&#xD;
          6. Known severe liver disease (e.g. cirrhosis, non-alcoholic steatohepatitis, sclerosing&#xD;
             cholangitis or hyperbilirubinemia)&#xD;
&#xD;
          7. Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)&#xD;
&#xD;
          8. Currently receiving prophylactic treatment of hepatitis B with anti-viral therapy&#xD;
&#xD;
          9. Known infection with human immunodeficiency virus (HIV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>January 8, 2019</last_update_submitted>
  <last_update_submitted_qc>January 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Crenolanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

